Investigating the circulating sphingolipidome response to a single high-intensity interval training session within healthy females and males in their twenties (SphingoHIIT): Protocol for a randomised controlled trial

Justin Carrard, Thomas Angst, Nadia Weber, Joëlle Bienvenue, Denis Infanger, Lukas Streese, Timo Hinrichs, Ilaria Croci, Christian Schmied, Hector Gallart-Ayala, Christoph Höchsmann, Karsten Koehler, Henner Hanssen, Julijana Ivanisevic, Arno Schmidt-Trucksäss, Justin Carrard, Thomas Angst, Nadia Weber, Joëlle Bienvenue, Denis Infanger, Lukas Streese, Timo Hinrichs, Ilaria Croci, Christian Schmied, Hector Gallart-Ayala, Christoph Höchsmann, Karsten Koehler, Henner Hanssen, Julijana Ivanisevic, Arno Schmidt-Trucksäss

Abstract

Introduction: Growing scientific evidence indicates that sphingolipids predict cardiometabolic risk, independently of and beyond traditional biomarkers such as low-density lipoprotein cholesterol. To date, it remains largely unknown if and how exercise, a simple, low-cost, and patient-empowering modality to optimise cardiometabolic health, influences sphingolipid levels. The SphingoHIIT study aims to assess the response of circulating sphingolipid species to a single session of high-intensity interval training (HIIT). Methods: This single-centre randomised controlled trial (RCT) will last 11 days per participant and aim to include 32 young and healthy individuals aged 20-29 (50% females). Participants will be randomly allocated to the HIIT (n= 16) or control groups (physical rest, n= 16). Participants will self-sample fasted dried blood spots for three consecutive days before the intervention (HIIT versus rest) to determine baseline sphingolipid levels. Dried blood spots will also be collected at five time points (2, 15, 30, 60min, and 24h) following the intervention (HIIT versus rest). To minimise the dietary influence, participants will receive a standardised diet for four days, starting 24 hours before the first dried blood sampling. For females, interventions will be timed to fall within the early follicular phase to minimise the menstrual cycle's influence on sphingolipid levels. Finally, physical activity will be monitored for the whole study duration using a wrist accelerometer. Ethics and dissemination: The Ethics Committee of Northwest and Central Switzerland approved this protocol (ID 2022-00513). Findings will be disseminated in scientific journals and meetings. Trial Registration The trial was registered on www.clinicaltrials.gov (NCT05390866, https://ichgcp.net/clinical-trials-registry/NCT05390866) on May 25, 2022.

Keywords: Cardiometabolic health; cardiovascular heatlh; ceramides; exercise; exercise medicine; physical activity; sphingolipids.

Conflict of interest statement

No competing interests were disclosed.

Copyright: © 2023 Carrard J et al.

Figures

Figure 1.. Sphingolipids as potential mediators of…
Figure 1.. Sphingolipids as potential mediators of the exercise effects on cardiometabolic health.
The SphingoHIIT study aims to investigate the effect of a single session of high-intensity interval training on circulating sphingolipids, which are novel biomarkers of cardiometabolic health. Abbreviations: HIIT = high-intensity interval training. This figure has been adapted with permission from Carrard, J.et al. A. How Ceramides Orchestrate Cardiometabolic Health—An Ode to Physically Active Living.Metabolites 2021,11, 675. https://doi.org/10.3390/metabo11100675
Figure 2.. Timeline of the SphingoHIIT study.
Figure 2.. Timeline of the SphingoHIIT study.
The SphingoHIIT study will last 11 days per participant. Following the baseline examination (which includes cardiopulmonary exercise testing), participants will have to avoid any vigorous-intensity physical activity (≥ 7 Metabolic Equivalent of Task) to maximise contrast between the pre-and post-intervention dried blood spots. To avoid potential confounding effects of food intake on circulating sphingolipids, participants will be fed starting 24h before the first dried blood spot collection. Abbreviations: CPET = cardiopulmonary exercise testing, HIIT = high-intensity interval training
Figure 3.. Illustrated sample size calculation.
Figure 3.. Illustrated sample size calculation.
A sample size of 16 participants per group was obtained (expressed as a detectable geometric mean ratio), assuming a power of 80%, an effect size of 1.19 (expressed as a geometric mean ratio), a standard deviation of 0.407 and a correlation coefficient ρ between pre-and post-intervention values of 0.8.
Figure 4.. Directed acyclic graph representing the…
Figure 4.. Directed acyclic graph representing the intervention effect on sphingolipid levels.
The intervention (HIIT vs physical rest) is defined as the exposure and sphingolipids as the outcomes. Due to the randomisation, the exposure has no ancestor. Thus, no variable influences simultaneously the exposure and outcomes, which implies that there is no confounding variable. Sex, body fat mass, CRF, and physical activity were identified as variables to be included in the statistical models to reduce the outcome variation and improve the precision of the average causal effect of the intervention on the sphingolipidome. Abbreviations: HIIT = high-intensity interval training, CRF = cardiorespiratory fitness, black triangle pointing to the right on green background = exposure, black bold vertical bar = outcomes, blue background = variables to be included in the statistical models to reduce the outcome variation and improve the precision of the average causal effect of the intervention. The figure was realised with http://www.dagitty.net.

References

    1. Lozano R, Naghavi M, Foreman K, et al. : Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. 10.1016/S0140-6736(12)61728-0
    1. Global, regional, and national disability-adjusted life years (DALYs) for diseases and injuries and healthy life expectancy (HALE), 1990 to 2019: quantifying the epidemiological transition. Seattle, WA: Institute for Health Metrics and Evaluation, University of Washington;[cited 13.07.2021].
    1. Benziger CP, Roth GA, Moran AE: The Global Burden of Disease Study and the Preventable Burden of NCD. Glob. Heart. 2016;11(4):393–397. 10.1016/j.gheart.2016.10.024
    1. Mach F, Baigent C, Catapano AL, et al. : 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2019;41(1):111–188. 10.1093/eurheartj/ehz455
    1. Wang M, Wang C, Han RH, et al. : Novel advances in shotgun lipidomics for biology and medicine. Prog. Lipid Res. 2016;61:83–108. 10.1016/j.plipres.2015.12.002
    1. Yang K, Han X: Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences. Trends Biochem. Sci. 2016;41(11):954–969. 10.1016/j.tibs.2016.08.010
    1. Checa A, Khademi M, Sar DG, et al. : Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Mult. Scler. 2015 Sep;21(10):1271–1279. 10.1177/1352458514561908
    1. Poss AM, Maschek JA, Cox JE, et al. : Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J. Clin. Invest. 2020;130(3):1363–1376. 10.1172/JCI131838
    1. Berkowitz L, Cabrera-Reyes F, Salazar C, et al. : Sphingolipid Profiling: A Promising Tool for Stratifying the Metabolic Syndrome-Associated Risk. Frontiers in Cardiovascular Medicine. 2022;8:8. 10.3389/fcvm.2021.785124
    1. Hannun YA, Obeid LM: Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 2018;19(3):175–191. 10.1038/nrm.2017.107
    1. Choi RH, Tatum SM, Symons JD, et al. : Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat. Rev. Cardiol. 2021;18(10):701–711. 10.1038/s41569-021-00536-1
    1. Laaksonen R, Ekroos K, Sysi-Aho M, et al. : Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J. 2016;37(25):1967–1976. 10.1093/eurheartj/ehw148
    1. Tippetts TS, Holland WL, Summers SA: Cholesterol - the devil you know; ceramide - the devil you don't. Trends Pharmacol. Sci. 2021;42(12):1082–1095. 10.1016/j.tips.2021.10.001
    1. Leiherer A, Mündlein A, Laaksonen R, et al. : Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients. Eur. J. Prev. Cardiol. 2021;29(6):947–956.
    1. Hilvo M, Jylhä A, Lääperi M, et al. : Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus. European Heart Journal Open. 2021;1(3).
    1. Nicholls M: Plasma ceramides and cardiac risk. Eur. Heart J. 2017;38(18):1359–1360. 10.1093/eurheartj/ehx205
    1. Vasile VC, Jaffe AS: An enhanced ceramide-based approach for primary prevention of atherosclerotic events. European Heart Journal Open. 2021;1(3) 10.1093/ehjopen/oeab016
    1. Hilvo M, Salonurmi T, Havulinna AS, et al. : Ceramide stearic to palmitic acid ratio predicts incident diabetes. Diabetologia. 2018;61(6):1424–1434. 10.1007/s00125-018-4590-6
    1. Carrard J, Gallart-Ayala H, Weber N, et al. : How Ceramides Orchestrate Cardiometabolic Health-An Ode to Physically Active Living. Metabolites. 2021;11(10) 10.3390/metabo11100675
    1. Chaurasia B, Talbot CL, Summers SA: Adipocyte Ceramides—The Nexus of Inflammation and Metabolic Disease. Front. Immunol. 2020;11(2282) 10.3389/fimmu.2020.576347
    1. Li W, Yang X, Xing S, et al. : Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall. Oxidative Med. Cell. Longev. 2014;2014:823071.
    1. Zhang X, Zhang Y, Wang P, et al. : Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism. Cell Metab. 2019;30(5):937–51.e5. 10.1016/j.cmet.2019.09.016
    1. Chaurasia B, Summers SA: Ceramides – Lipotoxic Inducers of Metabolic Disorders. Trends Endocrinol Metab. 2015;26(10):538–550. 10.1016/j.tem.2015.07.006
    1. Akawi N, Checa A, Antonopoulos AS, et al. : Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease. J. Am. Coll. Cardiol. 2021;77(20):2494–2513. 10.1016/j.jacc.2021.03.314
    1. Holland WL, Brozinick JT, Wang L-P, et al. : Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance. Cell Metab. 2007;5(3):167–179. 10.1016/j.cmet.2007.01.002
    1. Bikman BT, Guan Y, Shui G, et al. : Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. J. Biol. Chem. 2012;287(21):17426–17437. 10.1074/jbc.M112.359950
    1. Amati F, Dubé JJ, Alvarez-Carnero E, et al. : Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? Diabetes. 2011;60(10):2588–2597. 10.2337/db10-1221
    1. Tippetts TS, Holland WL, Summers SA: Cholesterol – the devil you know; ceramide – the devil you don’t. Trends Pharmacol. Sci. 2021;42(12):1082–1095. 10.1016/j.tips.2021.10.001
    1. Bull FC, Al-Ansari SS, Biddle S, et al. : World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br. J. Sports Med. 2020;54(24):1451–1462. 10.1136/bjsports-2020-102955
    1. Khan KM, Thompson AM, Blair SN, et al. : Sport and exercise as contributors to the health of nations. Lancet. 2012;380(9836):59–64. 10.1016/S0140-6736(12)60865-4
    1. Kohl HW, 3rd, Craig CL, Lambert EV, et al. : The pandemic of physical inactivity: global action for public health. Lancet. 2012;380(9838):294–305. 10.1016/S0140-6736(12)60898-8
    1. Pelliccia A, Sharma S, Gati S, et al. : 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur. Heart J. 2021;42(1):17–96. 10.1093/eurheartj/ehaa605
    1. Fiuza-Luces C, Santos-Lozano A, Joyner M, et al. : Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat. Rev. Cardiol. 2018;15(12):731–743. 10.1038/s41569-018-0065-1
    1. Cosentino F, Grant PJ, Aboyans V, et al. : 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020;41(2):255–323. 10.1093/eurheartj/ehz486
    1. Magkos F, Hjorth MF, Astrup A: Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2020;16(10):545–555. 10.1038/s41574-020-0381-5
    1. Carrard J, Guerini C, Appenzeller-Herzog C, et al. : The Metabolic Signature of Cardiorespiratory Fitness: A Systematic Review. Sports Med. 2021;7:e001008. 10.1136/bmjsem-2020-001008
    1. Bergman BC, Brozinick JT, Strauss A, et al. : Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am. J. Physiol. Endocrinol. Metab. 2015;309(4):E398–E408. 10.1152/ajpendo.00134.2015
    1. Kasumov T, Solomon TP, Hwang C, et al. : Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring). 2015;23(7):1414–1421. 10.1002/oby.21117
    1. Cerqueira É, Marinho DA, Neiva HP, et al. : Inflammatory Effects of High and Moderate Intensity Exercise—A Systematic Review. Front. Physiol. 2020;10. 10.3389/fphys.2019.01550
    1. Peterson LR, Xanthakis V, Duncan MS, et al. : Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J. Am. Heart Assoc. 2018;7(10): e007931. 10.1161/JAHA.117.007931
    1. Wewege MA, Ahn D, Yu J, et al. : High-Intensity Interval Training for Patients With Cardiovascular Disease-Is It Safe? A Systematic Review. J. Am. Heart Assoc. 2018;7(21):e009305. 10.1161/JAHA.118.009305
    1. Taylor JL, Holland DJ, Spathis JG, et al. : Guidelines for the delivery and monitoring of high intensity interval training in clinical populations. Prog. Cardiovasc. Dis. 2019;62(2):140–146. 10.1016/j.pcad.2019.01.004
    1. Weston KS, Wisløff U, Coombes JS: High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br. J. Sports Med. 2014;48(16):1227–1234. 10.1136/bjsports-2013-092576
    1. Bird SR, Hawley JA: Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport Exercise Medicine. 2017;2(1):e000143. 10.1136/bmjsem-2016-000143
    1. Campbell WW, Kraus WE, Powell KE, et al. : High-Intensity Interval Training for Cardiometabolic Disease Prevention. Med. Sci. Sports Exerc. 2019;51(6):1220–1226. 10.1249/MSS.0000000000001934
    1. Rahmati-Ahmadabad S, Azarbayjani MA, Farzanegi P, et al. : High-intensity interval training has a greater effect on reverse cholesterol transport elements compared with moderate-intensity continuous training in obese male rats. Eur. J. Prev. Cardiol. 2021;28(7):692–701. 10.1177/2047487319887828
    1. Falz R, Fikenzer S, Holzer R, et al. : Acute cardiopulmonary responses to strength training, high-intensity interval training and moderate-intensity continuous training. Eur. J. Appl. Physiol. 2019;119(7):1513–1523. 10.1007/s00421-019-04138-1
    1. Chua EC-P, Shui G, Lee IT-G, et al. : Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc. Natl. Acad. Sci. 2013;110(35):14468–14473. 10.1073/pnas.1222647110
    1. Gooley JJ: Circadian regulation of lipid metabolism. Proc. Nutr. Soc. 2016;75(4):440–450. 10.1017/S0029665116000288
    1. Hyötyläinen T, Orešič M: Optimizing the lipidomics workflow for clinical studies—practical considerations. Anal. Bioanal. Chem. 2015;407(17):4973–4993. 10.1007/s00216-015-8633-2
    1. Contrepois K, Wu S, Moneghetti KJ, et al. : Molecular Choreography of Acute Exercise. Cell. 2020;181(5):1112–30.e16. 10.1016/j.cell.2020.04.043
    1. Nayor M, Shah RV, Miller PE, et al. : Metabolic Architecture of Acute Exercise Response in Middle-Aged Adults in the Community. Circulation. 2020;142(20):1905–1924. 10.1161/CIRCULATIONAHA.120.050281
    1. Chow LS, Gerszten RE, Taylor JM, et al. : Exerkines in health, resilience and disease. Nat. Rev. Endocrinol. 2022;18(5):273–289. 10.1038/s41574-022-00641-2
    1. Cartier A, Hla T: Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 2019;366(6463):eaar5551. 10.1126/science.aar5551
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. : SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ: Br. Med. J. 2013;346:e7586. 10.1136/bmj.e7586
    1. Warburton DE, Jamnik VK, Bredin SS, et al. : The physical activity readiness questionnaire for everyone (PAR-Q+) and electronic physical activity readiness medical examination (ePARmed-X+). The Health & Fitness Journal of Canada. 2011;4(2):3–17.
    1. Hasin DS, O'Brien CP, Auriacombe M, et al. : DSM-5 criteria for substance use disorders: recommendations and rationale. Am. J. Psychiatry. 2013;170(8):834–851. 10.1176/appi.ajp.2013.12060782
    1. Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Prevention CfDCa. Alcohol Use and Your Health: Centers for Disease Control and Prevention. 2021.
    1. Riebe D, Franklin BA, Thompson PD, et al. : Updating ACSM’s Recommendations for Exercise Preparticipation Health Screening. Med. Sci. Sports Exerc. 2015;47(11):2473–2479. 10.1249/MSS.0000000000000664
    1. Efird J: Blocked randomization with randomly selected block sizes. Int. J. Environ. Res. Public Health. 2011;8(1):15–20.
    1. Anderson LJ, Erceg DN, Schroeder ET: Utility of multifrequency bioelectrical impedance compared with dual-energy x-ray absorptiometry for assessment of total and regional body composition varies between men and women. Nutr. Res. 2012;32(7):479–485. 10.1016/j.nutres.2012.05.009
    1. Buckinx F, Reginster JY, Dardenne N, et al. : Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. BMC Musculoskelet. Disord. 2015;16:60. 10.1186/s12891-015-0510-9
    1. Hansen JE, Sue DY, Wasserman K: Predicted values for clinical exercise testing. Am. Rev. Respir. Dis. 1984;129(2 Pt 2):S49–S55. 10.1164/arrd.1984.129.2P2.S49
    1. Scherr J, Wolfarth B, Christle JW, et al. : Associations between Borg’s rating of perceived exertion and physiological measures of exercise intensity. Eur. J. Appl. Physiol. 2013;113(1):147–155. 10.1007/s00421-012-2421-x
    1. Karlsen T, Aamot IL, Haykowsky M, et al. : High Intensity Interval Training for Maximizing Health Outcomes. Prog. Cardiovasc. Dis. 2017;60(1):67–77. 10.1016/j.pcad.2017.03.006
    1. Williams CJ, Gurd BJ, Bonafiglia JT, et al. : A Multi-Center Comparison of O2peak Trainability Between Interval Training and Moderate Intensity Continuous Training. Front. Physiol. 2019;10. 10.3389/fphys.2019.00019
    1. Mifflin MD, St Jeor ST, Hill LA, et al. : A new predictive equation for resting energy expenditure in healthy individuals. Am. J. Clin. Nutr. 1990;51(2):241–247. 10.1093/ajcn/51.2.241
    1. Hall KD, Sacks G, Chandramohan D, et al. : Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011;378(9793):826–837. 10.1016/S0140-6736(11)60812-X
    1. Hall KD, Chow CC: Estimating changes in free-living energy intake and its confidence interval. Am. J. Clin. Nutr. 2011;94(1):66–74. 10.3945/ajcn.111.014399
    1. Schmalenberger KM, Tauseef HA, Barone JC, et al. : How to study the menstrual cycle: Practical tools and recommendations. Psychoneuroendocrinology. 2021;123:104895. 10.1016/j.psyneuen.2020.104895
    1. Elliott-Sale KJ, Minahan CL, Jonge X, et al. : Methodological Considerations for Studies in Sport and Exercise Science with Women as Participants: A Working Guide for Standards of Practice for Research on Women. Sports Med. 2021;51(5):843–861. 10.1007/s40279-021-01435-8
    1. Cinelli C, Forney A, Pearl J: A crash course in good and bad controls. Available at SSRN 3689437. 2020.
    1. Carrard J, Angst T, Weber N, et al. : Investigating the circulating sphingolipidome response to a single high-intensity interval training session (SphingoHIIT): Protocol for a randomised controlled trial. 2022, November 27. 10.17605/
    1. Textor J, Zander B, Gilthorpe MS, et al. : Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. Int. J. Epidemiol. 2017;45(6):1887–1894.
    1. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological). 1995;57(1):289–300. 10.1111/j.2517-6161.1995.tb02031.x
    1. Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. 10.1136/bmj.c332
    1. Guideline IHT , editor. Clinical safety data management: definitions and standards for expedited reporting E2A. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 1994.
    1. : Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J Am Heart Assoc .2018;7(10) : 10.1161/JAHA.117.007931 10.1161/JAHA.117.007931

Source: PubMed

3
Iratkozz fel